Aquestive Therapeutics (AQST) reported Q4 net loss Wednesday of $0.19 per share, widening from a loss of $0.12 a year earlier.
Two analysts polled by FactSet expected a loss of $0.14.
Revenue for the quarter ended Dec. 31 was $11.9 million, down from $13.2 million a year earlier.
Analysts surveyed by FactSet expected $13.1 million.
For the full-year 2025, the company said it expects total revenue in the range of $47 million to $56 million. Analysts polled by FactSet expect $53 million.
Aquestive's stock was down 4.3% in after-hours activity Wednesday.
Price: 2.67, Change: -0.12, Percent Change: -4.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。